Unknown

Dataset Information

0

Clinical efficacy assessment in severe vernal keratoconjunctivitis: preliminary validation of a new penalties-adjusted corneal fluorescein staining score.


ABSTRACT: Introduction and objective: Vernal keratoconjunctivitis (VKC) is a rare allergic eye condition that occurs in children and is characterised by a combination of debilitating symptoms. Repeated use of topical corticosteroid rescue therapy is often necessary in severe forms. This study aims to assess the validity of a new composite endpoint: the penalties-adjusted corneal staining score (PACS-S) proposed as primary endpoint in VEKTIS trial evaluating the efficacy of a new corticosteroid-sparing treatment, VERKAZIA® (ciclosporin 1 mg/ml eye drops), in severe VKC patients. Methodology: This research comprised a systematic literature review to identify efficacy endpoints being proposed in clinical trials for pediatric patients with severe VKC, followed by a remote expert advisory board assessing the validity of the PACS-S. Results: While no agreed or validated endpoint for assessing efficacy in VKC was identified when VEKTIS trial started, the experts' board acknowledged a high face validity of PACS-S as a subjective integrated measure matching the current clinical practice. A fair external validity was considered with regards to VEKTIS trial secondary endpoints. Conclusion: PACS-S appears to be a reliable, valid and clinically meaningful primary endpoint that allows significant improvement over existing endpoints in severe VKC trials. Additional research is needed to validate this endpoint.

SUBMITTER: Leonardi A 

PROVIDER: S-EPMC7170307 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

Clinical efficacy assessment in severe vernal keratoconjunctivitis: preliminary validation of a new penalties-adjusted corneal fluorescein staining score.

Leonardi Andrea A   Dupuis-Deniaud Maëva M   Bremond-Gignac Dominique D  

Journal of market access & health policy 20200404 1


<b>Introduction and objective</b>: Vernal keratoconjunctivitis (VKC) is a rare allergic eye condition that occurs in children and is characterised by a combination of debilitating symptoms. Repeated use of topical corticosteroid rescue therapy is often necessary in severe forms. This study aims to assess the validity of a new composite endpoint: the penalties-adjusted corneal staining score (PACS-S) proposed as primary endpoint in VEKTIS trial evaluating the efficacy of a new corticosteroid-spar  ...[more]

Similar Datasets

| S-EPMC10381665 | biostudies-literature
| S-EPMC9376221 | biostudies-literature
| S-EPMC11008754 | biostudies-literature
| S-EPMC9039132 | biostudies-literature
| S-EPMC10382993 | biostudies-literature
| S-EPMC8441822 | biostudies-literature
| S-EPMC9046287 | biostudies-literature
| S-EPMC10084059 | biostudies-literature
| S-EPMC6396684 | biostudies-literature
| S-EPMC10828193 | biostudies-literature